Cell adhesion molecule CD44: Its functional roles in prostate cancer

American Journal of Translational Research

Volumn 3, Issue 1, 2011, Pages 1-7

  Iczkowski, Kenneth A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

CD44; Phenyl methylene hydantoins; Prostate; Silibinin; Splicing; Standard; Variant; Xenografts

Indexed keywords

CELL ADHESION MOLECULE; DOCETAXEL; HERMES ANTIGEN; HYALURONIC ACID; HYBRID PROTEIN; HYDANTOIN DERIVATIVE; LUCIFERASE; MICRORNA; OSTEOPONTIN; PHENYL METHYLENE HYDANTOIN DERIVATIVE; RETROVIRUS VECTOR; SILIBININ; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; DRUG SENSITIVITY; DRUG SENSITIZATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROENVIRONMENT; NONHUMAN; PROMOTER REGION; PROSTATE CANCER; RNA DEGRADATION; RNA INTERFERENCE; RNA TRANSLATION; SIGNAL TRANSDUCTION; SPONGE (PORIFERA); TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

SILYBUM MARIANUM;

EID: 78650207642     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Underhill C. CD44 - the hyaluronan receptor. J Cell Sci 1992;103:293-298.
2. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol 1993;54:271-335.
3. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992;89:12160-12164.
4. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008;18:260-267.
5. Okamoto I, Tsuiki H, Kenyon LC, Godwin AK, Emlet DR, Holgado-Madruga M, Lanham IS, Joynes CJ, Vo KT, Guha A, Matsumoto M, Ushio Y, Saya H, Wong AJ. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol 2002;160:441-447.
6. Cooper DL, Dougherty GJ. To metastasize or not -selection of CD44 splice sites. Nat Med 1995;1:95-97.
7. Tolg C, Hofmann M, Herrlich P, Ponta H. Splicing choice from 10 variant exons establishes CD44 variability. Nucleic Acids Res 1993;21:1225-1229.
8. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271:509-512.
9. Ishii S, Ford R, Thomas P, Nachman A, Steele G, Jessup JM. CD44 participates in the adhesion of human colorectal carcinoma cells to laminin and Type-IV collagen. Surg Oncol 1993;2:255-264.
10. Jalkanen S, Jalkanen M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol 1992;116:817-825.
11. Marhaba R, Zoller M. CD44 in cancer progression: Adhesion, migration and growth regulation. J Mol Histol 2004;35:211-231.
12. Legg JW, Lewis CA, Parsons M, Ng T, Isacke CM. A novel PKC-regulated mechanism controls CD44-ezrin association and directional cell motility. Nat Cell Biol 2002;4:399-407.
13. Lokeshwar VB, Bourguignon LYW. Posttranslational protein modification and expression of ankyrin-binding site(s) in Gp32 (Pgp-1/CD44) and its biosynthetic precursors during Tlymphoma membrane biosynthesis. J Biol Chem 1991;213:17983-17989.
14. Kallakury BVS, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, Fisher HAG, Kaufman R, Figge H, Ross JS. Decreased levels of CD44 protein and mRNA in prostate carcinoma - Correlation with tumor grade and ploidy. Cancer 1996;78:1461-1469.
15. De Marzo AM, Bradshaw C, Sauvageot J, Epstein JI, Miller GJ. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate 1998;34:162-168.
16. Iczkowski KA, Pantazis CG, Collins J. The loss of expression of CD44 standard and variant isoforms is related to prostatic carcinoma development and tumor progression. J Urol Pathol 1997;6:119-129.
17. Tran CP, Lin C, Yamashiro J, Reiter RE. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 2002;1:113-121.
18. Omara-Opyene AL, Qiu JX, Shah GV, Iczkowski KA. Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Lab Invest 2004;31:894-907.
19. Noordzij MA, vanSteenbrugge GJ, Verkaik NS, Schroder FH, vanderKwast TH. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res 1997;3:805-815.
20. Harada N, Mizoi T, Kinouchi M, Hoshi K, Ishii S, Shiiba K, Sasaki I, Matsuno S. Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer 2001;91:67-75.
21. Nagabhushan M, Pretlow TG, Guo YJ, Amini SB, Pretlow TP, Sy MS. Altered expression of CD44 in human prostate cancer during progression. Am J Clin Pathol 1996;106:647-651.
22. Iczkowski KA, Bai S, Pantazis CG. Prostate cancer overexpresses CD44 variants 7-9 at the messenger RNA and protein level. Anticancer Res 2003;23:3129-3140.
23. Yang K, Tang Y, Habermehl GK, Iczkowski KA. Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity. BMC Cancer 2010;10:16.
24. Liu W, Wei W, Winer D, Bamberger AM, Bamberger C, Wagener C, Essat S, Asa SL. CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene 2007;26:2747-2758.
25. Lou W, Krill D, Dhir R, Becich MJ, Dong JT, Frierson HF, Isaacs WB, Isaacs JT, Gao AC. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res 1999;59:2329-2331.
26. Kito H, Suzuki H, Ichikawa T, Sekita N, Kamiya N, Akakura K, Igarashi T, Nakayama T, Watanabe M, Harigaya K, Ito H. Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate 2001;49:110-115.
27. Verkaik NS, van Steenbrugge GJ, van Weerden WM, Bussemakers MJ, van der Kwast TH. Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. Lab Invest 2000;80:1291-1298.
28. Singal R, Ferdinand L, Reis IM, Schlesselman JJ. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep 2004;12:631-637.
29. Robbins EW, Travanty EA, Yang K, Iczkowski KA. MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells. BioMed Central Cancer 2008;8:260.
30. Thomas S, Muralidharan A, Shah GV. Knockdown of calcitonin receptor expression induces apoptosis and growth arrest of prostate cancer cells. Int J Oncol 2007;31:1425-1437.
31. Iczkowski KA, Omara-Opyene AL, Shah GV. The predominant CD44 splice variant in prostate cancer binds fibronectin, and calcitonin stimulates its expression. Anticancer Res 2006;26:2863-2872.
32. Iczkowski KA, Omara-Opyene AL, Kulkarni TR, Pansara M, Shah GV. Paracrine calcitonin in prostate cancer is linked to CD44 variant expression and invasion. Anticancer Res 2005;25:2075-2083.
33. Gao AC, Lou W, Sleeman JP, Isaacs JT. Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. Cancer Res 1998;7:2350-2352.
34. Noordzij MA, van Steenbrugge GJ, Schroder FH, Van der Kwast TH. Decreased expression of CD44 in metastatic prostate cancer. Int J Cancer 1999;84:478-483.
35. Handorean AM, Yang K, Flaig T, Robbins EW, Iczkowski KA. Silibinin suppresses CD44 expression in prostate cancer cells. Am J Transl Res 2009;1:80-87.
36. Flaig TW, Glodé M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 2010;17:848-855.
37. Shah GV, Muralidharan A, Thomas S, Gokulgandhi M, Mudit M, Khanfar M, El Sayed K. Identification of a small molecule class to enhance cellcell adhesion and attenuate prostate tumor growth and metastasis. Mol Cancer Ther 2009;8:509-520.
38. Yang K, Tang Y, Iczkowski KA. Phenyl-methylene hydantoins alter CD44-specific ligand binding of benign and malignant prostate cells and suppress CD44 isoform expression. Am J Transl Res 2010;2: 88-94.
39. Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, Suh N, DiPaola RS, Abate-Shen C. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clin Cancer Res 2006;12:5895-5901.
40. Yang ES, Maiorino CA, Roos BA, Knight SR, Burnstein KL. Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer. Mol Cell Endocrinol 2002;186:69-79.
41. Lambert JR, Young CD, Persons KS, Ray R. Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D3 derivative in prostate cancer cells. Biochem Biophys Res Commun 2007;361:189-195.
42. Huang Q, Gumireddy K, Schrier M, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nature Cell Biol 2008;10;202-210.
43. Yang K, Handorean AM, Iczkowski KA. MicroRNA 373 and 520c are downregulated in prostate cancer, suppress CD44 translation, and modulate prostate cancer cell invasion. Int J Clin Exp Pathol 2009;2:361-369.